Clinical aspects of melatonin in the acute coronary syndrome

Alberto Dominguez-Rodriguez, Pedro Abreu-Gonzalez, Russel J Reiter

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

This review considers the actions of an endogenously produced molecule, melatonin, on heart diseases. Recent research has shown that inflammation plays a key role in coronary heart disease (CHD) and other manifestations of atherosclerosis. Immune cells dominate early atherosclerotic lesions, their effector molecules accelerate progression of the lesions and activation of inflammation can elicit acute coronary syndromes (ACS). Scientific evidence from the last 15 years has suggested that melatonin has positive effects on the cardiovascular system. The presence of vascular melatoninergic receptor binding sites has been demonstrated; these receptors are functionally linked to vasoconstrictor or vasodilatory effects of melatonin. It has been shown that patients with CHD have a low melatonin production rate, especially those with higher risk of cardiac infarction and/or sudden death. Similarly to other organs and systems, the cardiovascular system exhibits diurnal and seasonal rhythms, including those in the heart rate, cardiac output and blood pressure. The suprachiasmatic nuclei of hypothalamus and, possibly, the melatoninergic system modulate the cardiovascular rhythms. The melatonin attenuates molecular and cellular damages resulting from cardiac ischemia/reperfusion in which destructive free radicals are involved. Anti-inflammatory and antioxidative properties of melatonin are also involved in the protection against vascular disease, i.e. atherosclerosis. The current brief summary of the literature provides an overview on the role of melatonin in the ACS.

Original languageEnglish (US)
Pages (from-to)367-373
Number of pages7
JournalCurrent Vascular Pharmacology
Volume7
Issue number3
DOIs
StatePublished - 2009

Fingerprint

Melatonin
Acute Coronary Syndrome
Cardiovascular System
Coronary Disease
Atherosclerosis
Inflammation
Suprachiasmatic Nucleus
Vasoconstrictor Agents
Circadian Rhythm
Sudden Death
Vascular Diseases
Cardiac Output
Infarction
Hypothalamus
Reperfusion
Free Radicals
Blood Vessels
Heart Diseases
Anti-Inflammatory Agents
Ischemia

Keywords

  • Acute coronary syndrome
  • Atherosclerosis
  • Coronary artery disease
  • Diurnal variations
  • Inflammation
  • Ischemia/reperfusion
  • Melatonin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Clinical aspects of melatonin in the acute coronary syndrome. / Dominguez-Rodriguez, Alberto; Abreu-Gonzalez, Pedro; Reiter, Russel J.

In: Current Vascular Pharmacology, Vol. 7, No. 3, 2009, p. 367-373.

Research output: Contribution to journalArticle

Dominguez-Rodriguez, Alberto ; Abreu-Gonzalez, Pedro ; Reiter, Russel J. / Clinical aspects of melatonin in the acute coronary syndrome. In: Current Vascular Pharmacology. 2009 ; Vol. 7, No. 3. pp. 367-373.
@article{02f7e3bc20cb4598b0b7e12a6ab4f510,
title = "Clinical aspects of melatonin in the acute coronary syndrome",
abstract = "This review considers the actions of an endogenously produced molecule, melatonin, on heart diseases. Recent research has shown that inflammation plays a key role in coronary heart disease (CHD) and other manifestations of atherosclerosis. Immune cells dominate early atherosclerotic lesions, their effector molecules accelerate progression of the lesions and activation of inflammation can elicit acute coronary syndromes (ACS). Scientific evidence from the last 15 years has suggested that melatonin has positive effects on the cardiovascular system. The presence of vascular melatoninergic receptor binding sites has been demonstrated; these receptors are functionally linked to vasoconstrictor or vasodilatory effects of melatonin. It has been shown that patients with CHD have a low melatonin production rate, especially those with higher risk of cardiac infarction and/or sudden death. Similarly to other organs and systems, the cardiovascular system exhibits diurnal and seasonal rhythms, including those in the heart rate, cardiac output and blood pressure. The suprachiasmatic nuclei of hypothalamus and, possibly, the melatoninergic system modulate the cardiovascular rhythms. The melatonin attenuates molecular and cellular damages resulting from cardiac ischemia/reperfusion in which destructive free radicals are involved. Anti-inflammatory and antioxidative properties of melatonin are also involved in the protection against vascular disease, i.e. atherosclerosis. The current brief summary of the literature provides an overview on the role of melatonin in the ACS.",
keywords = "Acute coronary syndrome, Atherosclerosis, Coronary artery disease, Diurnal variations, Inflammation, Ischemia/reperfusion, Melatonin",
author = "Alberto Dominguez-Rodriguez and Pedro Abreu-Gonzalez and Reiter, {Russel J}",
year = "2009",
doi = "10.2174/157016109788340749",
language = "English (US)",
volume = "7",
pages = "367--373",
journal = "Current Vascular Pharmacology",
issn = "1570-1611",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Clinical aspects of melatonin in the acute coronary syndrome

AU - Dominguez-Rodriguez, Alberto

AU - Abreu-Gonzalez, Pedro

AU - Reiter, Russel J

PY - 2009

Y1 - 2009

N2 - This review considers the actions of an endogenously produced molecule, melatonin, on heart diseases. Recent research has shown that inflammation plays a key role in coronary heart disease (CHD) and other manifestations of atherosclerosis. Immune cells dominate early atherosclerotic lesions, their effector molecules accelerate progression of the lesions and activation of inflammation can elicit acute coronary syndromes (ACS). Scientific evidence from the last 15 years has suggested that melatonin has positive effects on the cardiovascular system. The presence of vascular melatoninergic receptor binding sites has been demonstrated; these receptors are functionally linked to vasoconstrictor or vasodilatory effects of melatonin. It has been shown that patients with CHD have a low melatonin production rate, especially those with higher risk of cardiac infarction and/or sudden death. Similarly to other organs and systems, the cardiovascular system exhibits diurnal and seasonal rhythms, including those in the heart rate, cardiac output and blood pressure. The suprachiasmatic nuclei of hypothalamus and, possibly, the melatoninergic system modulate the cardiovascular rhythms. The melatonin attenuates molecular and cellular damages resulting from cardiac ischemia/reperfusion in which destructive free radicals are involved. Anti-inflammatory and antioxidative properties of melatonin are also involved in the protection against vascular disease, i.e. atherosclerosis. The current brief summary of the literature provides an overview on the role of melatonin in the ACS.

AB - This review considers the actions of an endogenously produced molecule, melatonin, on heart diseases. Recent research has shown that inflammation plays a key role in coronary heart disease (CHD) and other manifestations of atherosclerosis. Immune cells dominate early atherosclerotic lesions, their effector molecules accelerate progression of the lesions and activation of inflammation can elicit acute coronary syndromes (ACS). Scientific evidence from the last 15 years has suggested that melatonin has positive effects on the cardiovascular system. The presence of vascular melatoninergic receptor binding sites has been demonstrated; these receptors are functionally linked to vasoconstrictor or vasodilatory effects of melatonin. It has been shown that patients with CHD have a low melatonin production rate, especially those with higher risk of cardiac infarction and/or sudden death. Similarly to other organs and systems, the cardiovascular system exhibits diurnal and seasonal rhythms, including those in the heart rate, cardiac output and blood pressure. The suprachiasmatic nuclei of hypothalamus and, possibly, the melatoninergic system modulate the cardiovascular rhythms. The melatonin attenuates molecular and cellular damages resulting from cardiac ischemia/reperfusion in which destructive free radicals are involved. Anti-inflammatory and antioxidative properties of melatonin are also involved in the protection against vascular disease, i.e. atherosclerosis. The current brief summary of the literature provides an overview on the role of melatonin in the ACS.

KW - Acute coronary syndrome

KW - Atherosclerosis

KW - Coronary artery disease

KW - Diurnal variations

KW - Inflammation

KW - Ischemia/reperfusion

KW - Melatonin

UR - http://www.scopus.com/inward/record.url?scp=69149109844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69149109844&partnerID=8YFLogxK

U2 - 10.2174/157016109788340749

DO - 10.2174/157016109788340749

M3 - Article

VL - 7

SP - 367

EP - 373

JO - Current Vascular Pharmacology

JF - Current Vascular Pharmacology

SN - 1570-1611

IS - 3

ER -